Exploring Biological Linkage Between Circadian Disruption and Cancer Progression

September 22, 2019 updated by: Seoul National University Hospital

A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression

The purpose of this study is to explore the possible association between the circadian disruption and cancer progression.

Study Overview

Status

Completed

Conditions

Detailed Description

The biological markers that are assumed to bridge this association are measured and analyzed.

Study Type

Observational

Enrollment (Anticipated)

236

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
    • Jongno-gu
      • Seoul, Jongno-gu, Korea, Republic of, 140-013
        • Seoul National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

University (Tertiary) hospital, oncology clinic

Description

Inclusion Criteria:

  • Age: 18-70
  • Breast cancer patients who are getting chemotherapy for the first time in life
  • Patients are either having stage 4 cancer or starting neoadjuvant chemotherapy.
  • Patient have signed on the informed consent, and well understood the objective and procedure of this study

Exclusion Criteria:

  • Patients already have received chemotherapy
  • Patient had another cancer (except thyroid cancer) within 5 years
  • Patient with severe medical condition
  • Patient had taken psychiatric medication more than 1 month in life
  • Patient worked the night shift for more than 1 month in 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Breast cancer
Diagnosed breast cancer patients who are getting chemotherapy for the first time.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free survival
Time Frame: 3 years (and more) after recruitment
The data progression-free survival will be done by reviewing patients' medical record.
3 years (and more) after recruitment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Circadian disruption
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire will be used during assessment.
Baseline, after 1 month, after 6 month, after 12 month
Objective sleep cycle measures
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
The assessment will be performed by using actigraph and sleep diary.
Baseline, after 1 month, after 6 month, after 12 month
Physiological measures
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
The measures include blood pressure, body temperature, skin conductance, breathing pattern, and Electroencephalography.
Baseline, after 1 month, after 6 month, after 12 month
Sleep quality measures
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
The measurements will be performed using Epworth sleepiness scale, Pittsburgh Sleep Quality Index, and Insomnia Severity Index.
Baseline, after 1 month, after 6 month, after 12 month
Quality of Life measure
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
The measurement will be performed using M.D. Anderson Symptom Inventory.
Baseline, after 1 month, after 6 month, after 12 month
Cancer related Fatigue
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
Fatigue severity scale will be used during the assessment.
Baseline, after 1 month, after 6 month, after 12 month
Distress related measure
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
Hospital Anxiety and Depression Scale will be used during the assessment.
Baseline, after 1 month, after 6 month, after 12 month
Posttraumatic Stress-related symptom measure
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
Impact of Event Scale-revised will be used to categorize and quantify Posttraumatic stress-related symptom in cancer patients.
Baseline, after 1 month, after 6 month, after 12 month
Menopausal symptom measure
Time Frame: Baseline, after 1 month, after 6 month, after 12 month
Menopause Rating Scale will be used during the assessment.
Baseline, after 1 month, after 6 month, after 12 month
Personality measure
Time Frame: Baseline
Temperament and Character Inventory will be used to examine the personality factor in each participant.
Baseline
Genetic polymorphism
Time Frame: Baseline
Variable Number Tandem Repeat and Single Nucleotide Polymorphism of circadian-rhythm related genes will be examined.
Baseline
Epigenetic Change
Time Frame: Baseline
The methylation specific Polymerase Chain Reaction technique will be used to explore methylation patterns in circadian clock gene or in a global gene level.
Baseline
Cortisol level
Time Frame: Baseline
Salivary cortisol level will be measured multiple times at baseline.
Baseline
Melatonin
Time Frame: Baseline
Salivary or Urine melatonin level will be measured.
Baseline
Inflammatory markers
Time Frame: Baseline
The various inflammation markers will be measured from blood sample.
Baseline
Overall survival
Time Frame: 3 years (and more) after recruitment
The data progression-free survival will be done by reviewing patients' medical record.
3 years (and more) after recruitment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 10, 2013

Primary Completion (ACTUAL)

February 15, 2019

Study Completion (ACTUAL)

June 15, 2019

Study Registration Dates

First Submitted

December 10, 2013

First Submitted That Met QC Criteria

December 12, 2013

First Posted (ESTIMATE)

December 13, 2013

Study Record Updates

Last Update Posted (ACTUAL)

September 24, 2019

Last Update Submitted That Met QC Criteria

September 22, 2019

Last Verified

April 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BreastCA_circa_mech

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Neoplasms

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe